Business
NeOnc Technologies Holdings, Inc. Appoints Dr. Victoria Medvec to Board of Directors
Dr. Medvec adds extensive knowledge of high-stakes issues including mergers and acquisitions and partnerships to the NeOnc team WESTLAKE VILLAGE, Calif.,
About this update from Neonc Technologies Holdings, Inc.
[{"type":"text","content":"Dr. Medvec adds extensive knowledge of high-stakes issues including mergers and acquisitions and partnerships to the NeOnc team\nWESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol NTHI), a clinical-stage medical biotechnology company, announced today that Dr. Victoria Medvec, has been appointed to its Board of Directors. Dr. Medvec is the Chief Executive Officer of Medvec and Associates, a valued adviser to executives and boards at a substantial portion of Fortune 100 companies. \"We are thrilled to leverage Victoria's extensive experience in strategic partnerships, global market access, and regulatory negotiations,” said Dr. Thomas Chen, Chief Executive Officer of NeOnc. “She brings invaluable expertise on high-stakes issues including mergers and acquisitions, customer contracts, and supplier agreements, among others. Over her illustrious career, Victoria has advised prominent life sciences clients such as Amgen, AstraZeneca, Bristol Myers Squibb, Gilead, Pfizer, and Sanofi. Her presence on our Board enhances our potential for success, and will be invaluable as we work toward the successful commercialization of central nervous system therapeutics.\" With a wealth of experience as a public and private board director, Dr. Medvec employs her expertise in negotiations and decision making to help companies drive revenue growth through optimization, risk management, corporate governance and mergers and acquisitions. Her research has been published in esteemed academic journals including Psychological Review and the Journal of Personality and Social Psychology. Additionally, she is the author of the best-selling book \"Negotiate Without Fear.\" \"I am honored to join NeOnc's Board of Directors at such an exciting time,\" said Dr. Medvec. \"I am passionate about the Company’s commitment to advancing innovative therapies for patients in need, and I look forward to working alongside a talented team to support NeOnc in achieving its mission to bring transformative solutions to patients living with debilitating brain tumors.\" “Dr. Medvec’s strategic value to our company is significant,” said Amir Heshmatpour, NeOnc’s Executive Chairman. “We anticipate receiving significant benefits from her insights and guidance as NeOnc advances its inf...